$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000143774924025853 Filed on August 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$83.88M	$73.47M	$16.07M
YoY Change	-49.41%	357.05%	2606.06%
Cost Of Revenue	$9.341M	$8.304M	$1.911M
YoY Change	166.2%	334.54%	8208.7%
Gross Profit	$74.54M	$65.16M	$14.16M
YoY Change	-54.08%	360.09%	2380.39%
Gross Profit Margin	88.86%	88.7%	88.11%
Selling, General & Admin	$41.97M	$38.79M	$30.72M
YoY Change	28.07%	26.29%	143.04%
% of Gross Profit	56.3%	59.53%	216.87%
Research & Development	$20.14M	$17.56M	$28.12M
YoY Change	36.5%	-37.57%	4.64%
% of Gross Profit	27.02%	26.94%	198.56%
Depreciation & Amortization	$11.00K	$19.00K	$32.00K
YoY Change	-84.29%	-40.63%	-58.97%
% of Gross Profit	0.01%	0.03%	0.23%
Operating Expenses	$62.10M	$56.35M	$58.84M
YoY Change	30.68%	-4.23%	48.91%
Operating Profit	$12.43M	$8.816M	-$44.67M
YoY Change	-89.17%	-119.73%	14.72%
Interest Expense	-$10.83M	-$3.977M	-$3.627M
YoY Change	-391.73%	9.65%	20.22%
% of Operating Profit	-87.12%	-45.11%
Other Income/Expense, Net	$2.666M	-$2.265M	$691.0K
YoY Change	-412.18%	-427.79%	-52.28%
Pretax Income	$4.268M	$6.551M	-$47.61M
YoY Change	-96.25%	-113.76%	17.53%
Income Tax	$388.0K	-$328.0K	$0.00
% Of Pretax Income	9.09%	-5.01%
Net Earnings	$3.880M	$6.879M	-$47.61M
YoY Change	-96.59%	-114.45%	17.53%
Net Earnings / Revenue	4.63%	9.36%	-296.19%
Basic Earnings Per Share	$0.03	$0.05	-$0.34
Diluted Earnings Per Share	$0.02	$0.04	-$0.34
COMMON SHARES
Basic Shares Outstanding	154.8M	154.5M	149.4M
Diluted Shares Outstanding	160.7M	159.4M	141.5M

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$341.0M	$217.3M	$144.9M
YoY Change	48.8%	49.93%	-25.96%
Cash & Equivalents	$195.8M	$82.91M	$97.01M
Short-Term Investments	$145.2M	$134.3M	$47.90M
Other Short-Term Assets	$32.63M	$7.047M	$11.09M
YoY Change	170.11%	-36.44%	63.95%
Inventory	$84.67M	$81.24M	$30.23M
Prepaid Expenses
Receivables	$115.7M	$83.61M	$17.48M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$574.1M	$389.2M	$208.6M
YoY Change	79.89%	86.58%	2.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.411M	$7.663M	$206.0K
YoY Change	5472.18%	3619.9%	-98.12%
Goodwill			$799.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.125M	$947.0K	$0.00
YoY Change			-100.0%
Other Assets	$2.114M	$2.155M	$1.279M
YoY Change	62.62%	68.49%	1.03%
Total Long-Term Assets	$11.95M	$12.06M	$12.28M
YoY Change	-0.07%	-1.82%	-74.99%
TOTAL ASSETS
Total Short-Term Assets	$574.1M	$389.2M	$208.6M
Total Long-Term Assets	$11.95M	$12.06M	$12.28M
Total Assets	$586.0M	$401.2M	$220.9M
YoY Change	77.01%	81.66%	-12.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$101.4M	$93.47M	$62.95M
YoY Change	155.43%	48.5%	69.1%
Accrued Expenses	$11.32M	$7.657M	$8.153M
YoY Change	15.47%	-6.08%	86.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$125.1M	$108.7M	$72.67M
YoY Change	116.92%	49.54%	67.72%
LONG-TERM LIABILITIES
Long-Term Debt	$244.2M	$102.5M	$97.70M
YoY Change	146.85%	4.95%	41.7%
Other Long-Term Liabilities	$24.59M	$12.44M	$10.03M
YoY Change	153.45%	23.96%	-3.13%
Total Long-Term Liabilities	$244.2M	$102.5M	$97.70M
YoY Change	146.85%	4.95%	23.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$125.1M	$108.7M	$72.67M
Total Long-Term Liabilities	$244.2M	$102.5M	$97.70M
Total Liabilities	$393.9M	$223.6M	$180.4M
YoY Change	136.84%	23.97%	47.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.600B	-$1.600B	-$1.614B
YoY Change	6.67%	-0.86%
Common Stock	$156.0K	$155.0K	$151.0K
YoY Change	3.31%	2.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.400M
YoY Change
Treasury Stock Shares
Shareholders Equity	$192.2M	$177.6M	$40.45M
YoY Change
Total Liabilities & Shareholders Equity	$586.0M	$401.2M	$220.9M
YoY Change	77.01%	81.66%	-12.24%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	$3.880M	$6.879M	-$47.61M
YoY Change	-96.59%	-114.45%	17.53%
Depreciation, Depletion And Amortization	$11.00K	$19.00K	$32.00K
YoY Change	-84.29%	-40.63%	-58.97%
Cash From Operating Activities	-$12.21M	$5.536M	-$42.00M
YoY Change	-114.58%	-113.18%	-14.48%
INVESTING ACTIVITIES
Capital Expenditures	$24.00K		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$9.310M	$1.765M	$30.50M
YoY Change	-69.2%	-94.21%	193.87%
Cash From Investing Activities	-$9.334M	$1.765M	$30.50M
YoY Change	-69.12%	-94.21%	193.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	134.5M	135.0K	47.05M
YoY Change	31912.86%	-99.71%	34749.63%
NET CHANGE
Cash From Operating Activities	-12.21M	5.536M	-42.00M
Cash From Investing Activities	-9.334M	1.765M	30.50M
Cash From Financing Activities	134.5M	135.0K	47.05M
Net Change In Cash	112.9M	7.436M	35.54M
YoY Change	109.49%	-79.08%	-192.08%
FREE CASH FLOW
Cash From Operating Activities	-$12.21M	$5.536M	-$42.00M
Capital Expenditures	$24.00K		$0.00
Free Cash Flow	-$12.23M		-$42.00M
YoY Change	-114.61%		-14.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154873847
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151465598
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154832538
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151424289
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	800000	usd
CY2021Q4	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2024Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32639
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3898269
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3020 Carrington Mill Blvd, Suite 475
	dei	Entity Address City Or Town EntityAddressCityOrTown	Morrisville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27560
	dei	City Area Code CityAreaCode	877
	dei	Local Phone Number LocalPhoneNumber	575-8489
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	TGTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	154823137
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82910000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92933000	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	134342000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	124575000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	83608000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	51093000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	81243000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	39823000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	7047000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9519000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	389150000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	317943000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1292000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1285000	usd
CY2024Q2	us-gaap	Long Term Investments LongTermInvestments	947000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7663000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8050000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2155000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2309000	usd
CY2024Q2	us-gaap	Assets Assets	401207000	usd
CY2023Q4	us-gaap	Assets Assets	329587000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	93472000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	38471000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4162000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1479000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1306000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1446000	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3373000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	152000	usd
CY2024Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	6351000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	12172000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	108664000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53720000	usd
CY2024Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3743000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6016000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	102537000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	100118000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8695000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9231000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	223639000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	169085000	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	155000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	151000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1734052000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1713162000	usd
CY2024Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	234000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	234000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1556405000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1552577000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	177568000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	160502000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	401207000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	329587000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73466000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16074000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	136939000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23877000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8304000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1911000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13745000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2768000	usd
CY2024Q2	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	2520000	usd
CY2023Q2	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	5664000	usd
	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	4972000	usd
	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	7247000	usd
CY2024Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	15036000	usd
CY2023Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	22458000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	45306000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	36744000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17556000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28122000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50278000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43991000	usd
CY2024Q2	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	6962000	usd
CY2023Q2	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	6877000	usd
	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	13848000	usd
	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	12117000	usd
CY2024Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	31828000	usd
CY2023Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	23838000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	59522000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	46666000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38790000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30715000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	73370000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58783000	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	64650000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	60748000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	137393000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	105542000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	8816000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-44674000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-454000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-81665000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3977000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3627000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	6265000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	6471000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1712000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	691000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2592000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1295000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2265000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2936000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3673000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5176000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6551000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47610000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4127000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-86841000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-328000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-299000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	6879000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-47610000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3828000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-86841000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144727482
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141503738
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145464255
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	140911295
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	159423571
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141503738
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145464255
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	140911295
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	58587000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	363000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	595000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7120000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-39232000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27433000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	751000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46297000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	13582000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-47610000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	40453000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	160502000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	10304000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10707000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	160109000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	135000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	10445000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	6879000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	177568000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3828000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-86841000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	18820000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	19364000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3470000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	487000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1278000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1100000	usd
	tgtx	Amortization Of Leasehold Interest AmortizationOfLeaseholdInterest	106000	usd
	tgtx	Amortization Of Leasehold Interest AmortizationOfLeaseholdInterest	106000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	905000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	990000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-178000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-0	usd
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-24000	usd
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-261000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	39491000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28896000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2540000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	9316000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	32515000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17484000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	49181000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	19136000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1193000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1187000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3646000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1323000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1100000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-76000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2671000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101907000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	144900000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	46501000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	151265000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	22168000	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1125000	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	-0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7490000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24333000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46296000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	145000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1114000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	25000000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	-0	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	125000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	145000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72285000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10016000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5289000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	94218000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103577000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	84202000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	98288000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82910000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97009000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	1292000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	1279000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84202000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98288000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4936000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3929000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1600000000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	217300000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14873637
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13456358
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	6879000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-47610000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3828000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-86841000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144727482
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141503738
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145464255
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	140911295
CY2024Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	14696089
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	159423571
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141503738
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145464255
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	140911295
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73466000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16074000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	136939000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23877000	usd
CY2024Q2	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	134342000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	2000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	15000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	134329000	usd
CY2023Q4	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	124575000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	30000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	53000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	124552000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1735000	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	77893000	usd
CY2024Q2	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	1615000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	81243000	usd
CY2024Q2	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	947000	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	947000	usd
CY2024Q2	tgtx	Forward Contract Liabilities ForwardContractLiabilities	2703000	usd
CY2024Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	381000	usd
CY2024Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3084000	usd
CY2023Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	357000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	357000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9500000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12500000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18800000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19400000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9500000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18800000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4697029
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	29750
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	-0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4667279
CY2023Q1	tgtx	Debt Instrument Fee Percentage Of Aggregate Principle Amount DebtInstrumentFeePercentageOfAggregatePrincipleAmount	0.0495	pure
CY2024Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	95000000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	95000000	usd
CY2024Q2	tgtx	Long Term Debt Accreted Liability Of Final Payment Fee LongTermDebtAccretedLiabilityOfFinalPaymentFee	11371000	usd
CY2023Q4	tgtx	Long Term Debt Accreted Liability Of Final Payment Fee LongTermDebtAccretedLiabilityOfFinalPaymentFee	10230000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	106371000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	105230000	usd
CY2024Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3834000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	5112000	usd
CY2024Q2	tgtx	Longterm Debt Before Repayments LongtermDebtBeforeRepayments	102537000	usd
CY2023Q4	tgtx	Longterm Debt Before Repayments LongtermDebtBeforeRepayments	100118000	usd
	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	0	usd
CY2023	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	0	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	102537000	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	100118000	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	-0	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	-0	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	102537000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	100118000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	551000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	552000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1151000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1096000	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	551000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	552000	usd
	us-gaap	Lease Cost LeaseCost	1151000	usd
	us-gaap	Lease Cost LeaseCost	1096000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1001	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1306000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1446000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8695000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9231000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	10001000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10677000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1195000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2100000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2080000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1913000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1827000	usd
CY2024Q2	tgtx	Lessee Operating Lease Liability To Be Paid Year Five And Therafter LesseeOperatingLeaseLiabilityToBePaidYearFiveAndTherafter	4715000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13830000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3829000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	10001000	usd
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1025	pure
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	900000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	500000	usd

Files In Submission

Name	View Source	Status
0001437749-24-025853-index-headers.html	Edgar Link	pending
0001437749-24-025853-index.html	Edgar Link	pending
0001437749-24-025853.txt	Edgar Link	pending
0001437749-24-025853-xbrl.zip	Edgar Link	pending
ex_678351.htm	Edgar Link	pending
ex_678352.htm	Edgar Link	pending
ex_678353.htm	Edgar Link	pending
ex_678354.htm	Edgar Link	pending
ex_711621.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tgtx-20240630.xsd	Edgar Link	pending
tgtx20240630_10q.htm	Edgar Link	pending
tgtx-20240630_def.xml	Edgar Link	unprocessable
tgtx-20240630_lab.xml	Edgar Link	unprocessable
tgtx-20240630_pre.xml	Edgar Link	unprocessable
tgtx20240630_10q_htm.xml	Edgar Link	completed
tgtx-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2024 Q3 Form 10-Q Financial Statement

#000143774924025853 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2024 Q3 Form 10-Q Financial Statement

#000143774924025853 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx